EDP Sciences logo
Search
Menu
All issues Volume 44 / No 3 (May-June 2004) Reprod. Nutr. Dev., 44 3 (2004) 263-271 References
Free Access
Issue
Reprod. Nutr. Dev.
Volume 44, Number 3, May-June 2004
Page(s) 263 - 271
DOI https://doi.org/10.1051/rnd:2004031
References of Reprod. Nutr. Dev. 44 263-271
  1. Durand G, Guesnet Ph, Chalon S, Alessandri JM, Rizkalla S, Lebranchu Y. Importance nutritionnelle des acides gras polyinsaturés. In: Aliments Fonctionnels, Marcel Roberfroid (Ed), Éditions Tec & Doc-Lavoisier, Paris, 2002, p 193-219.
  2. Rioux V, Daval S, Guillou H, Jan S, Legrand P. Although it is rapidly metabolized in cultured rat hepatocytes, lauric acid is used for protein acylation. Reprod Nutr Dev 2003, 43: 419-430 [EDP Sciences] [PubMed].
  3. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002, 21: 495-505.
  4. Roberts LJ, Fessel JP. The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Chem Phys Lipids 2004, 128: 173-186 [PubMed].
  5. Cracowski JL. Isoprostanes: an emerging role in vascular physiology and disease? Chem Phys Lipids 2004, 128: 75-83.
  6. Khan SA, Vanden Heuvel JP. Role of nuclear receptors in the regulation of gene expression by dietary fatty acids. J Nutr Biochem 2003, 14: 554-567.
  7. Clarke S. Polyunsaturated Fatty Acid Regulation of Gene Transcription: A Molecular Mechanism to Improve the Metabolic Syndrome. J Nutr 2001, 131: 1129-1132.
  8. Kromann N, Green A. Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950-1974. Acta Med Scand 1980, 208: 401-406.
  9. Ailhaud G, Guesnet P. Fatty acid composition of fats is an early determinant of childhood obesity: a short review and an opinion. Obes Rev 2004, 5: 21-26.
  10. Emsley R, Oosthuizen P, van Rensburg SJ. Clinical potential of omega-3 fatty acids in the treatment of schizophrenia. CNS Drugs 2003, 17: 1081-1091.
  11. Astorg P. Acides gras polyinsaturés n-3 et dépression : des espoirs pour la prévention et la thérapeutique. NAFAS 2003, 1: 3-11.
  12. Abeywardena MY, Head RJ. Long chain n-3 polyunsaturated fatty acids and blood vessel function. Cardiovasc Res 2001, 52: 361-371.
  13. Delarue J, Le Foll C, Corporeau C, Lucas D. n-3 long chain polyunsaturated fatty acids: a nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity? Reprod Nutr Dev 2004, 44: 287-257.
  14. Massiera F, Saint-Marc P, Seydoux J, Murata T, Kobayashi T, Narumiya S, Guesnet P, Amri EZ, Negrel R, Ailhaud G. Arachidonic acid and prostacyclin signaling promote adipose tissue development: a human health concern? J Lipid Res 2003, 44: 271-279.
  15. Colas S, Paon L, Denis F, Prat M, Louisot P, Hoinard C, Le Floch O, Ogilvie G, Bougnoux P. Enhanced radiosensitivity of rat autochthonous mammary tumors by dietary docosahexaenoic acid. Int J Cancer 2004, 109: 449-454.
  16. Maillard V, Bougnoux P, Ferrari P, Jourdan ML, Pinault M, Lavillonniere F, Body G, Le Floch O, Chajes V. n-3 and n-6 fatty acids in breast adipose tissue and relative risk of breast cancer in a case-control study in Tours, France. Int J Cancer 2002, 98: 78-83 [CrossRef] [PubMed].
  17. Bougnoux P, Maillard V, Ferrari P, Jourdan ML, Chajes V. n-3 fatty acids and breast cancer. IARC Sci Publ 2002, 156: 337-341 [PubMed].
  18. Prentice RL. Future possibilities in the prevention of breast cancer. Fat and fiber and breast cancer research. Breast Cancer Res 2000, 2: 268-276.
  19. Berrino F, Krogh V, Riboli E. Epidemiology studies on diet and cancer. Tumori 2003, 89: 581-585.
  20. Haag M. Essential fatty acids and the brain. Can J Psychiatry 2003, 48: 195-203.
  21. Guesnet P, Alessandri JM. Acides gras polyinsaturés du lait et développement du système nerveux central du nouveau-né. Cah Nutr Diet 1995, 30: 109-116.
  22. Innis SM. Perinatal biochemistry and physiology of long-chain polyunsaturated fatty acids. J Pediatr 2003, 143: S1-S8.
  23. Delion S, Chalon S, Guilloteau D, Besnard JC, Durand G. Alpha-Linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J Neurochem 1996, 66: 1582-1591.
  24. Zimmer L, Vancassel S, Cantagrel S, Breton P, Delamanche S, Guilloteau D, Durand G, Chalon S. The dopamine mesocorticolimbic pathway is affected by deficiency in n-3 polyunsaturated fatty acids. Am J Clin Nutr 2002, 75: 662-667.
  25. Aid S, Vancassel S, Poumes-Ballihaut C, Chalon S, Guesnet P, Lavialle M. Effect of a diet-induced n-3 PUFA depletion on cholinergic parameters in the rat hippocampus. J Lipid Res 2003, 44: 1545-1551.
  26. Chalon S, Vancassel S, Zimmer L, Guilloteau D, Durand G. Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission. Lipids 2001 36: 937-944.
  27. Vancassel S. Oméga 3 et neurotransmission cérébrale. OCL 2004, 11: 58-65.
  28. Skosnik PD, Yao JK. From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia? Prostaglandins Leukot Essent Fat Acids 2003, 69: 367-384.
  29. Emsley R, Oosthuizen P, Van Rensburg SJ. Clinical potential of omega-3 fatty acids in the treatment of schizophrenia. CNS Drugs 2003, 17: 1081-1091.
  30. Logan AC. Neurobehavioral aspects of omega-3 fatty acids: possible mechanisms and therapeutic value in major depression. Altern Med Rev 2003, 8: 410-425.
  31. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, Aggarwal N, Schneider J. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003, 60: 940-946.
  32. Kalmijn S. Fatty acid intake and the risk of dementia and cognitive decline: a review of clinical and epidemiological studies. J Nutr Health Aging 2000, 4: 202-207.
  33. Guesnet P, Couet C, Alessandri JM, Antoine JM, Durand G. Variabilité de la teneur en acide linoléique (18:2n-6) et du rapport 18:2n-6/18:3n-3 des lipides dans le lait de femme en France. Ann Pédiatr 1995, 42: 282-288.